Welcome to our dedicated page for RIGEL PHARMACEUTICALS SEC filings (Ticker: RIGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rigel Pharmaceuticals' SEC filings document the regulatory record of a Delaware biotechnology company with common stock listed on Nasdaq under RIGL. Its 8-K reports frequently furnish operating results, product revenue trends, collaboration revenue and business updates tied to TAVALISSE, GAVRETO, REZLIDHIA and development programs such as R289.
The filings also cover material agreements, license and collaboration disclosures, capital-structure information for common stock, and governance matters. Proxy materials describe shareholder voting items, board matters, executive compensation and equity awards, while material-event filings record changes affecting agreements, financial reporting and corporate governance.
Rigel Pharmaceuticals has entered into an exclusive, royalty-bearing worldwide license agreement with Arvinas entities and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant) and related products. VEPPANU is approved in the United States for certain ER+, HER2‑negative, ESR1‑mutated advanced or metastatic breast cancer.
Rigel will pay an upfront $70 million, up to $15 million tied to transition activities, and up to $320 million in potential regulatory and sales milestone payments, plus tiered royalties from the mid‑teens to mid‑twenties on net sales. Rigel will lead global development and commercialization, while reimbursing specified ongoing development costs up to $40 million. The agreement becomes effective after expiration or termination of the applicable Hart‑Scott‑Rodino antitrust waiting period.
Rigel Pharmaceuticals, Inc. ownership disclosure: Soleus Capital Master Fund, L.P. and affiliated entities report beneficial ownership of 968,108 shares of Rigel common stock, representing 5.2% of the class. The percentage is calculated using 18,502,080 shares outstanding as of April 30, 2026 per Rigel's Form 10-Q cover.
The filing attributes the shares to the Master Fund and describes the ownership/management chain (Soleus Capital, LLC; Soleus Capital Group, LLC; Soleus Capital Management, L.P.; Soleus GP, LLC) and a disclaimer of beneficial ownership by related entities, signed by Guy Levy.
Rigel Pharmaceuticals reported first quarter 2026 total revenues of $58.8 million, driven by $54.9 million in net product sales and $3.9 million in contract revenues from collaborations. Net product sales rose 26% year over year, reflecting growth across its hematology-oncology portfolio.
TAVALISSE net product sales were $37.3 million, up 31%, GAVRETO reached $9.6 million, up 7%, and REZLIDHIA generated $8.0 million, up 31% versus the same period in 2025. Rigel posted net income of $8.7 million, or $0.47 basic and $0.44 diluted per share, compared with $11.4 million a year earlier, as total costs and expenses increased to $46.9 million on higher R&D and commercial spending.
Cash, cash equivalents and short-term investments were $146.7 million as of March 31, 2026. The company reaffirmed its 2026 outlook for total revenues of approximately $275–$290 million, including net product sales of $255–$265 million and contract revenues of $20–$25 million, and continues to anticipate positive full-year net income while funding ongoing clinical programs such as R289.
Rigel Pharmaceuticals reported a profitable first quarter of 2026 with higher product sales and continued investment in its pipeline. Total revenues were $58.8 million, up from $53.3 million a year earlier, driven by net product sales of $54.9 million. TAVALISSE, REZLIDHIA and GAVRETO net sales were $37.3 million, $8.0 million and $9.6 million, respectively, each growing versus 2025.
Net income was $8.7 million compared with $11.4 million, as operating expenses and a higher $3.0 million tax provision offset revenue gains. Diluted EPS was $0.44. Cash, cash equivalents and short‑term investments totaled $146.7 million, with $45.0 million of term debt outstanding at March 31, 2026 and operating cash flow of $2.7 million.
Rigel highlighted progress in its R289 Phase 1b study and broader olutasidenib collaborations in hematologic cancers and high‑grade glioma. The company received notice in April 2026 that Eli Lilly will terminate their global RIPK1 collaboration effective June 15, 2026, after which Rigel expects to regain full rights to the compounds. In May 2026 Rigel refinanced its term loan into a new $40.0 million revolving credit facility with MidCap.
Rigel Pharmaceuticals reports that Eli Lilly and Company has elected to terminate their License and Collaboration Agreement covering ocadusertib (previously R552) and other RIPK1 inhibitors. Lilly’s termination is in its entirety and becomes effective June 15, 2026.
The agreement, signed on February 18, 2021, had granted Lilly an exclusive worldwide license to develop and commercialize RIPK1 inhibitors for non-CNS and CNS diseases, with potential milestone payments and royalties to Rigel. After termination, Lilly’s rights to the licensed compounds will cease, subject to transition provisions, and Rigel expects to regain full rights to these programs.
Rigel is evaluating the impact of the termination and, following this step and the earlier end of the CNS disease program effective in November 2025, does not expect to receive future milestones or royalties under the agreement.
Rigel Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 14, 2026. Stockholders will elect three directors to serve until the 2029 annual meeting, approve amendments to its equity incentive and employee stock purchase plans, cast an advisory vote on executive pay, and ratify Ernst & Young LLP as independent auditor for 2026.
The equity proposals would add 500,000 shares to the 2018 Equity Incentive Plan and 360,000 shares to the 2000 Employee Stock Purchase Plan. As of March 19, 2026, there were 18,480,019 shares of common stock outstanding and entitled to vote. The board unanimously recommends voting “FOR” all five proposals.
Rigel Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class as disclosed. The amendment explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report holdings separately.
Rigel Pharmaceuticals reported very strong fourth quarter and full-year 2025 results driven by its hematology and oncology portfolio. Fourth quarter 2025 total revenues were $69.8 million, with net product sales of $65.4 million, up 41% from 2024, and contract revenues of $4.4 million. Net income for the quarter surged to $268.1 million, or $13.54 diluted per share, largely reflecting a $245.9 million non-cash deferred income tax benefit.
For 2025, total revenues were $294.3 million, including $232.0 million of net product sales, which grew 60% year over year, and $62.3 million of contract revenues. Full-year net income was $367.0 million, or $19.48 diluted per share. Cash, cash equivalents and short-term investments increased to $155.0 million as of December 31, 2025, from $77.3 million a year earlier.
Rigel continues to advance its pipeline, particularly the Phase 1b study of R289 in lower-risk myelodysplastic syndrome, with dose expansion enrollment ongoing and recommended Phase 2 dose selection expected in the second half of 2026. For 2026, the company anticipates total revenues of $275 to $290 million and positive net income while funding existing and new clinical programs.
Rigel Pharmaceuticals outlines a growing hematology and oncology business built around three FDA‑approved drugs and a developing pipeline. In 2025, TAVALISSE net sales reached $158.8 million, up 51.6% from 2024, while REZLIDHIA sales grew to $31.0 million and GAVRETO to $42.1 million.
The company is advancing R289 for lower‑risk myelodysplastic syndromes, with Phase 1b data showing durable transfusion independence in some heavily pretreated patients and Orphan Drug and Fast Track designations. Rigel also expands olutasidenib into new indications through collaborations with MD Anderson and CONNECT, while a settlement on TAVALISSE patents allows a generic entrant no earlier than the second quarter of 2032.
Rigel Pharmaceuticals director Walter H. Moos reported option and share transactions. On February 20, 2026, he exercised a stock option for 4,000 shares of common stock at $24.00 per share through a derivative exercise or conversion.
On the same date, he sold 4,000 shares of common stock in an open-market or private transaction at $36.36 per share. After these transactions, he directly owned 12,722 shares of Rigel Pharmaceuticals common stock. The reported numbers reflect a prior one-for-ten reverse stock split.